208 related articles for article (PubMed ID: 34907331)
1. Optimizing immunotherapy for colorectal cancer.
Ganesh K
Nat Rev Gastroenterol Hepatol; 2022 Feb; 19(2):93-94. PubMed ID: 34907331
[TBL] [Abstract][Full Text] [Related]
2. Evaluating Immunotherapy in Nonmetastatic Colorectal Cancer.
Sinicrope FA
Oncology (Williston Park); 2019 May; 33(5):178-80. PubMed ID: 31095716
[No Abstract] [Full Text] [Related]
3. Immunotherapy in colorectal cancer with mismatch repair deficiency.
Overman MJ
Clin Adv Hematol Oncol; 2019 May; 17(5):265-267. PubMed ID: 31188802
[No Abstract] [Full Text] [Related]
4. Labetuzumab govitecan in metastatic colorectal cancer.
Das M
Lancet Oncol; 2017 Oct; 18(10):e563. PubMed ID: 28844817
[No Abstract] [Full Text] [Related]
5. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer.
Chen Y; Zheng X; Wu C
Front Immunol; 2021; 12():792691. PubMed ID: 34925375
[TBL] [Abstract][Full Text] [Related]
6. The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy.
Kamal Y; Schmit SL; Frost HR; Amos CI
Immunotherapy; 2020 Oct; 12(14):1083-1100. PubMed ID: 32787587
[TBL] [Abstract][Full Text] [Related]
7. HER2 and immunotherapy using monoclonal antibodies in colorectal cancer.
Nazemalhosseini Mojarad E; Kuppen PJ
Immunotherapy; 2013 Dec; 5(12):1267-9. PubMed ID: 24283833
[No Abstract] [Full Text] [Related]
8. Current advancements and future perspectives of immunotherapy in colorectal cancer research.
Kishore C; Bhadra P
Eur J Pharmacol; 2021 Feb; 893():173819. PubMed ID: 33347822
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in colorectal cancer.
Le DT
Clin Adv Hematol Oncol; 2018 Jan; 16(1):22-24. PubMed ID: 29741500
[No Abstract] [Full Text] [Related]
10. The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine.
Riley JM; Cross AW; Paulos CM; Rubinstein MP; Wrangle J; Camp ER
Cancer; 2018 Apr; 124(8):1650-1659. PubMed ID: 29315503
[TBL] [Abstract][Full Text] [Related]
11. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
12. Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts.
Ghalamfarsa F; Khatami SH; Vakili O; Taheri-Anganeh M; Tajbakhsh A; Savardashtaki A; Fazli Y; Uonaki LR; Shabaninejad Z; Movahedpour A; Ghalamfarsa G
Immunotherapy; 2021 Nov; 13(16):1355-1367. PubMed ID: 34641708
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in colorectal cancer.
Agarwal P; Le DT; Boland PM
Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613
[TBL] [Abstract][Full Text] [Related]
14. Colorectal Cancer Immunotherapy: Options and Strategies.
Johdi NA; Sukor NF
Front Immunol; 2020; 11():1624. PubMed ID: 33042104
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?
Martin-Romano P; Adam J; Scoazec JY; Gouy S; Levy A; Baldini C; Champiat S; Soria JC; Massard C; Marabelle A; Deutsch E; Hollebecque A
Front Immunol; 2021; 12():745146. PubMed ID: 34804027
[TBL] [Abstract][Full Text] [Related]
16. The colorectal cancer immune microenvironment and approach to immunotherapies.
Koi M; Carethers JM
Future Oncol; 2017 Aug; 13(18):1633-1647. PubMed ID: 28829193
[No Abstract] [Full Text] [Related]
17. Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens.
Moradi A; Pourseif MM; Jafari B; Parvizpour S; Omidi Y
Pharmacol Res; 2020 Jun; 156():104790. PubMed ID: 32278043
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab for the treatment of colorectal cancer.
Coupez D; Hulo P; Touchefeu Y; Bossard C; Bennouna J
Expert Opin Biol Ther; 2020 Mar; 20(3):219-226. PubMed ID: 31952453
[No Abstract] [Full Text] [Related]
19. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
20. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
